Press Releases


Cullgen: boosting the breadth of e3 ligases for protein degradation

September 9, 2019 - Cullgen Emerging Company Profile published by BioCentury

Cullgen Receives $16 Million Series A Investment to Advance Pipeline of Targeted Protein Degraders

April 10, 2019 - Series A financing led by two leading global venture capital firms – Sequoia Capital China and HighLight Capital.


Cullgen Announces Expanded Scientific Advisory Board

July 18, 2018 - DELAWARE - Cullgen Inc, (“Cullgen” or the “Company), a drug discovery company focused on development of drug candidates using uSMITE™ (ubiquitin mediated small molecule induced target elimination), announced that Dr. Timothy Heffernan and Dr. Michele Pagano have joined the Company’s Scientific Advisory Board (SAB).


Executives of Cullgen to Present at International Conferences

July 11, 2018 - DELAWARE - Executives of Cullgen Inc. ("Cullgen") have been invited to present research findings at three international drug discovery conferences in US and China.


Cullgen Announces Publication by Co-Founders in European Journal of Medicinal Chemistry

April 3, 2018 - DELAWARE - Cullgen Inc., a biopharmaceutical company focusing on developing new drugs using protein degradation technology today announced that the laboratories of its co-founders, Dr. Jian Jin and Dr. Yue Xiong, have published an article in European Journal of Medicinal Chemistry featuring first-in-class small-molecule degraders of Anaplastic Lymphoma Kinase.


Cullgen Announces Seed Financing

March 1, 2018 - TOKYO, JAPAN – Cullgen Inc. ("Cullgen") today announced a Seed Financing of up to $15M by GNI Group Ltd. (GNIG) (TOKYO: 2160) to build a new drug discovery platform based on advanced ubiquitin-mediated protein degradation technology.